They've selected a Contract Research Organization for Europe, which should get that trial moving forwards:
BETHESDA, MD, February 15, 2013 -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW
Bio), a biotechnology company developing DCVax® personalized immune therapies for solid
tumor cancers, announced today that, building upon nearly three years of manufacturing
development, regulatory processes and clinical preparations in Europe, the Company has named
a leading international contract research organization (CRO) to manage the Company’s 312-
patient Phase III clinical trial for Glioblastoma multiforme (GBM) brain cancer in Europe.
Engaging a first class CRO was one of the last steps required for initiating enrollment in the U.K.
After an extensive RFP process, the Company selected PAREXEL International. PAREXEL is a
leading international CRO with unparalleled expertise in managing international clinical trials.
Over the past 30 years, they have developed significant expertise in oncology, including
glioblastoma. Headquartered near Boston, Massachusetts, they operate in 71 locations
throughout 54 countries around the world, and have over 14,000 employees.
This must be the reason the centers were not open yet. Now they will open in the near future and we will see about patient enrollment over seas . It would be a good time to take advantage of the grant fron Germany, if succesfull thier will be plenty more grants to follow. IMHO It is a buy and hold folks the price is right. GLTA